HOME
ABOUT
CONSULTING
RESOURCES
USEFUL LINKS
CONTACT US

 

Consulting

Dr. Seibold works closely with biotechnology and pharmaceutical companies in an effort to successfully develop new therapies for scleroderma and its complications.

He has extensive experience and expertise in many areas including Raynaud phenomenon, disease-modifying therapies, pulmonary hypertension and interstitial lung disease.

His past consultancies have included:

1984-1989
Janssen Pharmaceutica – ketanserin 
1989-1996
Berlex Laboratories – intravenous and oral iloprost 
1989-1997
Connetics Corporation – recombinant human relaxin 
1989-1998
Merck Foundation – clinical pharmacology training 
2000-present
Genzyme Corporation – TGF trapping strategies
2000-present
FibroGen Corporation – monoclonal to CTGF
2001-present
Actelion Pharmaceuticals – bosentan in scleroderma
2003-present
United Therapeutics – treprostinil in scleroderma
2004-present
Encysive – sitaxsentan in scleroderma
2004-present
CoTherix – inhaled iloprost in scleroderma
2005-present
Celgene – imids in scleroderma
2005-present
Millennium – CCR2RA in scleroderma
2006-present
Pfizer, Inc – PDGF antagonism in scleroderma
2008-present
Centocor, Inc – TH-17 biology in scleroderma
2008-present
Actelion Pharmaceuticals – early diagnosis of PAH
2008-present
United Therapeutics – oral treprostinil in digital ulcers
2009- present
United Therapeutics – prevention of PAH in scleroderma
2010-present
Pfizer, Inc. – sitaxsentan in scleroderma
2010-present
Apricus Biosciences – topical alprostadil in Raynaud phenomenon
2010-present
Sanofi-Aventis – therapies for fibrosing disorders
2010-present
Pfizer, Inc. – PDE5I for Raynaud phenomenon
2010-present
Pfizer, Inc. – computer modeling in pulmonary hypertension
2011-present
Genentech – anti-IL6 in scleroderma
2011-present
Boehringer Ingelheim – TKI inn scleroderma
2012-present
Bayer – riociguat in scleroderma

Click here to view his full curriculum vitae.